613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Validation and Retraining of the Stellae-123 Gene Expression Signature Improved Risk Stratification in Taiwanese Acute Myeloid Leukemia Patients

Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Cont

Association between BMI and Survival in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

TP53 Y220C Mutations in Patients with Myeloid Malignancies

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

Improvement in Survival of Patients with FLT3 Mutated Acute Myeloid Leukemia: Results from a Retrospective Canadian Cohort

Extended Nutritional Monitoring in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia

Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy

Identification of Characteristics and Prognostic Impact of FUS-ERG and AML1-MTG16 Fusion Genes in Adult AML Patients

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Effectiveness of Intensive Chemotherapy with 7+3 Versus Vidaza and Venetoclax in Acute Myeloid Leukemia with Sequential Stem Cell Transplant: Results

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH-Mutated AML

Derivation of a Risk Prediction Model for Venous Thromboembolism in Adult Patients with Acute Myeloid Leukemia

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Global Burden and Trends of Acute Myeloid Leukemia Attributable to High Body Mass Index in 38 OECD Countries between 1990-2019: A Benchmarking Systema

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Trial in Progress: Investigating the Prognostic Significance of Malnutrition and Sarcopenia in Older Adults with Acute Myeloid Leukemia

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for In

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All-Trans Retinoic Acid (A

European pediatric Acute Leukemia (EuPAL) Registry

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1: Time to Reconsider Prognostic Risk? a Study from th

Biallelic Landscape of DNMT3A Mutant Myeloid Neoplasia

Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study